Search Results - "THOME, D"

microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease by Thome, Aaron D, Harms, Ashley S, Volpicelli-Daley, Laura A, Standaert, David G

“…Increasing evidence points to inflammation as a chief mediator of Parkinson's disease (PD), a progressive neurodegenerative disorder characterized by loss of…”
Get full text

Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease by Williams, Gregory P, Schonhoff, Aubrey M, Jurkuvenaite, Asta, Thome, Aaron D, Standaert, David G, Harms, Ashley S

“…Parkinson's disease (PD) is characterized by intracellular alpha-synuclein (α-syn) inclusions, progressive death of dopaminergic neurons in the substantia…”
Get full text

α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration by Harms, Ashley S, Delic, Vedad, Thome, Aaron D, Bryant, Nicole, Liu, Zhiyong, Chandra, Sidhanth, Jurkuvenaite, Asta, West, Andrew B

“…Genetic variation in a major histocompatibility complex II (MHCII)-encoding gene (HLA-DR) increases risk for Parkinson disease (PD), and the accumulation of…”
Get full text

Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease by Thome, Aaron D, Standaert, David G, Harms, Ashley S

“…Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopamine neurons in the substantia nigra pars compacta (SNpc) and…”
Get full text

Functional alterations of myeloid cells during the course of Alzheimer's disease by Thome, Aaron D, Faridar, Alireza, Beers, David R, Thonhoff, Jason R, Zhao, Weihua, Wen, Shixiang, Pascual, Belen, Masdeu, Joseph C, Appel, Stanley H

“…Neuroinflammation is a hallmark of neurodegenerative disease and a significant component of the pathology of Alzheimer's disease (AD). Patients present with…”
Get full text

Extracellular Vesicles Derived From Ex Vivo Expanded Regulatory T Cells Modulate In Vitro and In Vivo Inflammation by Thome, Aaron D., Thonhoff, Jason R., Zhao, Weihua, Faridar, Alireza, Wang, Jinghong, Beers, David R., Appel, Stanley H.

“…Extracellular vehicles (EVs) are efficient biomarkers of disease and participate in disease pathogenesis; however, their use as clinical therapies to modify…”
Get full text

Short-chain fatty acids induced lung tumor cell death and increased peripheral blood CD4+ T cells in NSCLC and control patients ex vivo by Thome, Carolin D, Tausche, Patrick, Hohenberger, Katja, Yang, Zuqin, Krammer, Susanne, Trufa, Denis I, Sirbu, Horia, Schmidt, Joachim, Finotto, Susetta

“…Despite therapy advances, one of the leading causes of cancer deaths still remains lung cancer. To improve current treatments or prevent non-small cell lung…”
Get full text

Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's disease by Faridar, Alireza, Vasquez, Matthew, Thome, Aaron D, Yin, Zheng, Xuan, Hui, Wang, Jing Hong, Wen, Shixiang, Li, Xuping, Thonhoff, Jason R, Zhao, Weihua, Zhao, Hong, Beers, David R, Wong, Stephen T C, Masdeu, Joseph C, Appel, Stanley H

“…Regulatory T cells (Tregs) play a neuroprotective role by suppressing microglia and macrophage-mediated inflammation and modulating adaptive immune reactions…”
Get full text

Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease by Thome, Aaron D., Atassi, Farah, Wang, Jinghong, Faridar, Alireza, Zhao, Weihua, Thonhoff, Jason R., Beers, David R., Lai, Eugene C., Appel, Stanley H.

“…Inflammation is a pathological hallmark of Parkinson’s disease (PD). Chronic pro-inflammatory responses contribute to the loss of neurons in the…”
Get full text

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease by Faridar, Alireza, Eid, Abdulmunaim M, Thome, Aaron D, Zhao, Weihua, Beers, David R, Pascual, Maria B, Nakawah, Mohammad O, Roman, Gustavo C, Davis, Charles S, Grundman, Michael, Masdeu, Joseph C, Appel, Stanley H

“…ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic. gov/ct2/show/NCT05821153…”
Get full text

The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia by Ponnazhagan, Ranjani, Harms, Ashley S., Thome, Aaron D., Jurkuvenaite, Asta, Gogliotti, Rocco, Niswender, Colleen M., Conn, P. Jeffrey, Standaert, David G.

“…While the specific trigger of Parkinson Disease (PD) in most patients is unknown, considerable evidence suggests that the neuroinflammatory response makes an…”
Get full text

Immunosuppressive Functions of M2 Macrophages Derived from iPSCs of Patients with ALS and Healthy Controls by Zhao, Weihua, Beers, David R., Thonhoff, Jason R., Thome, Aaron D., Faridar, Alireza, Wang, Jinghong, Wen, Shixiang, Ornelas, Loren, Sareen, Dhruv, Goodridge, Helen S., Svendsen, Clive N., Appel, Stanley H.

“…Amyotrophic lateral sclerosis (ALS) is a disorder with immune alterations that augment disease severity. M2 macrophages benefit diabetic and nephrotic mice by…”
Get full text

Serum programmed cell death proteins in amyotrophic lateral sclerosis by Beers, David R., Zhao, Weihua, Thonhoff, Jason R., Faridar, Alireza, Thome, Aaron D., Wen, Shixiang, Wang, Jinghong, Appel, Stanley H.

“…Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem pro-inflammatory neuromuscular disorder. Activation of programmed cell death-1 (PD-1), and…”
Get full text

Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone by Leung, Nelson, Thomé, Stephan D, Dispenzieri, Angela

Get full text

Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease by Harms, Ashley S., Thome, Aaron D., Yan, Zhaoqi, Schonhoff, Aubrey M., Williams, Gregory P., Li, Xinru, Liu, Yudong, Qin, Hongwei, Benveniste, Etty N., Standaert, David G.

“…Accumulation of alpha-synuclein (α-syn) in the central nervous system (CNS) is a core feature of Parkinson disease (PD) that leads to activation of the innate…”
Get full text

MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration by Harms, Ashley S, Cao, Shuwen, Rowse, Amber L, Thome, Aaron D, Li, Xinru, Mangieri, Leandra R, Cron, Randy Q, Shacka, John J, Raman, Chander, Standaert, David G

“…Accumulation of α-synuclein (α-syn) in the brain is a core feature of Parkinson disease (PD) and leads to microglial activation, production of inflammatory…”
Get full text

Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in ALS by Beers, David R., Thonhoff, Jason R., Faridar, Alireza, Thome, Aaron D., Zhao, Weihua, Wen, Shixiang, Appel, Stanley H.

“…Oxidative stress (OS) induces inflammation, which in turn exacerbates OS and the expression of acute phase proteins (APPs). Regulatory T lymphocyte (Treg)…”
Get full text

Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis by Beers, David R., Zhao, Weihua, Neal, Daniel W., Thonhoff, Jason R., Thome, Aaron D., Faridar, Alireza, Wen, Shixiang, Wang, Jinghong, Appel, Stanley H.

“…Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem pro-inflammatory neuromuscular disorder compromising muscle function resulting in death…”
Get full text

Advancing head and neck cancer management: Unveiling the diagnostic and therapeutic potentials of molecular profiling by Baral, Binav, Suleiman, Riham, Fazer‐Posorske, Casey A., Ma, Daniel J., McGarrah, Patrick W., Thome, Stephan D., Molina, Julian R., Price, Katharine A., Halfdanarson, Thorvardur R., Fuentes, Harry E.

“…Background Head and neck cancers (HNC) present diagnostic challenges due to multifocal disease manifestations, posing difficulties in distinguishing between…”
Get full text

Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? by GILL, Sharlene, LOPRINZI, Charles L, LABIANCA, Roberto, WEI CHEN, CHA, Stephen S, HELDEBRANT, Michael P, GOLDBERG, Richard M, SARGENT, Daniel J, THOME, Stephan D, ALBERTS, Steven R, HALLER, Daniel G, BENEDETTI, Jacqueline, FRANCINI, Guido, SHEPHERD, Lois E, SEITZ, Jean Francois

“…Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the…”
Get full text